AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31198489 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal skin diagnostic testing with intradermal injections of Progesterone, Estradiol, Estrone, and Estriol; followed by serial desensitization injections
Number of subjects: 35
Study 31198489 — intervention group
Group type: COMPARATOR
Intervention: Placebo solvent injections
Number of subjects: 35
Study 31198551 — intervention group
Group type: EXPERIMENTAL
Intervention: Triceps lifting approach
Number of subjects: 43
Study 31198551 — intervention group
Group type: COMPARATOR
Intervention: Olecranon osteotomy
Number of subjects: 43
Study 31198606 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV with ILM peeling
Number of subjects: 22
Study 31198661 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mailing of fecal screening tests
Number of subjects: 18226
Study 31198661 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 18226
Study 31198947 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal aflatoxin exposure (measured via AFB1-lysine adduct concentration)
Number of subjects: 1621
Study 31198947 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal aflatoxin exposure
Number of subjects: 1621
Study 31199305 — intervention group
Group type: EXPERIMENTAL
Intervention: HITSystem 2.0
Number of subjects: 108
Study 31199324 — intervention group
Group type: EXPERIMENTAL
Intervention: CliniPup (serious game for health)
Number of subjects: 20
Study 31199324 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 20
Study 31199326 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-care intervention (electronic PrEP, ePrEP)
Number of subjects: 0
Study 31199326 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 0
Study 31199334 — intervention group
Group type: EXPERIMENTAL
Intervention: eCDSS (electronic clinical decision support system) integrated into primary care workflows.
Number of subjects: 995
Study 31199334 — intervention group
Group type: EXPERIMENTAL
Intervention: eCDSS (electronic clinical decision support system)
Number of subjects: 995
Study 31199335 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) provided for up to 3 months upon request, along with continuous smoking cessation (SC) counseling and behavioral support.
Number of subjects: 1184
Study 31199335 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous smoking abstinence (SA) verified at each visit using self-reporting and chemical verification.
Number of subjects: 1184
Study 31199335 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of effect assessed in urine and blood at baseline, Month 3, Month 6, and Month 12.
Number of subjects: 1184
Study 31199335 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessments included adverse events and serious adverse events, body weight, vital signs, spirometry, electrocardiogram, clinical chemistry, hematology and urine analysis safety panel, physical examination, and concomitant medications.
Number of subjects: 1184
Study 31199341 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct treatment components tailored for YMSM including assertive communication training videos and motivational interviewing focused on assisting with identification and development (MI-AID) before CHTC.
Number of subjects: 24
Study 31199341 — intervention group
Group type: COMPARATOR
Intervention: Most successful adapted intervention package from Phase 2.
Number of subjects: 24
Study 31199347 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousal feedback-based exposure therapy
Number of subjects: 50
Study 31199347 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 50
Study 31199799 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair cortisol levels in sarcoidosis patients
Number of subjects: 32
Study 31199799 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair testosterone levels in sarcoidosis patients
Number of subjects: 32
Study 31199799 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of hair cortisol with anxiety
Number of subjects: 32
Study 31199799 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of hair cortisol with depression
Number of subjects: 32
Study 31199799 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of hair cortisol with SF-36 mental domain
Number of subjects: 32
Study 31199799 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of hair cortisol with fatigue
Number of subjects: 32
Study 31199858 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cerebral microbleeds (CMB) detected via MRI
Number of subjects: 65
Study 31199860 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 4189
Study 31199860 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 4189
Study 31200009 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of an anaesthetic nurse and experienced anaesthesiologist
Number of subjects: 3535
Study 31200009 — intervention group
Group type: COMPARATOR
Intervention: Anaesthesiologist's experience <15 years and absence of anaesthetic nurse
Number of subjects: 3535
Study 31200009 — intervention group
Group type: COMPARATOR
Intervention: Overall complications
Number of subjects: 3535
Study 31200729 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation phase included one session of sub-motor threshold, sensory electrical stimulation followed by neuromuscular electrical stimulation paired with ear movement feedback for up to 8 additional sessions.
Number of subjects: 10
Study 31200729 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill acquisition phase using an auricular control device that used sEMG signals to control movements of a cursor through three levels of computer games.
Number of subjects: 10
Study 31200729 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation and skill phases of training.
Number of subjects: 10
Study 31200729 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation phase training.
Number of subjects: 10
Study 31200729 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall training protocol.
Number of subjects: 10
Study 31201031 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth with Down syndrome
Number of subjects: 226
Study 31201031 — intervention group
Group type: COMPARATOR
Intervention: Controls (youth without Down syndrome)
Number of subjects: 226
Study 31201085 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalation of TKI treatment to half the standard dose for 12 months, then stopped for a further 24 months.
Number of subjects: 174
Study 31201169 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab (DARA) 16 mg/kg
Number of subjects: 0
Study 31201169 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous bortezomib (1.3-1.5 mg/m2)
Number of subjects: 0
Study 31201186 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory Brainstem Implant (ABI)
Number of subjects: 10
Study 31201592 — intervention group
Group type: EXPERIMENTAL
Intervention: RV pacing (RVP)
Number of subjects: 14
Study 31201592 — intervention group
Group type: COMPARATOR
Intervention: LBBB
Number of subjects: 14
Study 31201592 — intervention group
Group type: EXPERIMENTAL
Intervention: RVP
Number of subjects: 14
Study 31202287 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Supervision (CS) agencies in rural areas
Number of subjects: 0
Study 31202287 — intervention group
Group type: COMPARATOR
Intervention: Community Supervision (CS) agencies in urban areas
Number of subjects: 0
Study 31202757 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31202772 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tube potentials (≤80 kVp)
Number of subjects: 4006
Study 31202772 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tube potentials (90 to 100 kVp)
Number of subjects: 4006
Study 31202772 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tube potentials
Number of subjects: 4006
Study 31202772 — intervention group
Group type: COMPARATOR
Intervention: Conventional tube potentials
Number of subjects: 4006
Study 31202772 — intervention group
Group type: COMPARATOR
Intervention: CCTA with 90 to 100 kVp
Number of subjects: 4006
Study 31203228 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 2578
Study 31203237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia-specific respite care concept (DESKK) including mobility training for PwD and counselling for FCs
Number of subjects: 0
Study 31203390 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein combined with FOLFOX or FOLFOX-Bevacizumab
Number of subjects: 13
Study 31203390 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein
Number of subjects: 13
Study 31203498 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus Aflibercept
Number of subjects: 31
Study 31203649 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTi)
Number of subjects: 62
Study 31203649 — intervention group
Group type: COMPARATOR
Intervention: Sleep Management Control (SMC)
Number of subjects: 62
Study 31203649 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BBTi and SMC)
Number of subjects: 62
Study 31204071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincter-preserving surgery
Number of subjects: 203
Study 31204145 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloading knee brace for three months
Number of subjects: 41
Study 31204145 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (60-min session, three times a week for three months)
Number of subjects: 41
Study 31204595 — intervention group
Group type: EXPERIMENTAL
Intervention: IN.PACT Admiral Drug-Coated Balloon
Number of subjects: 0
Study 31204775 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding (40% above baseline energy requirements for 8 weeks)
Number of subjects: 35
Study 31204775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-than-predicted SMR (basal EE) during follow-up
Number of subjects: 35
Study 31204775 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-than-predicted sedentary 24h-EE during follow-up
Number of subjects: 35
Study 31205473 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose antivenom
Number of subjects: 155
Study 31205473 — intervention group
Group type: COMPARATOR
Intervention: Low dose antivenom
Number of subjects: 155
Study 31205473 — intervention group
Group type: EXPERIMENTAL
Intervention: Preantivenom subcutaneous adrenaline (SCAd)
Number of subjects: 155
Study 31205473 — intervention group
Group type: EXPERIMENTAL
Intervention: IV adrenaline infusion (IVAI)
Number of subjects: 155
Study 31205473 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 155
Study 31205629 — intervention group
Group type: EXPERIMENTAL
Intervention: 1L imatinib (IM)
Number of subjects: 266
Study 31205629 — intervention group
Group type: EXPERIMENTAL
Intervention: 1L dasatinib (DAS)
Number of subjects: 266
Study 31205629 — intervention group
Group type: EXPERIMENTAL
Intervention: 1L nilotinib (NIL)
Number of subjects: 266
Study 31205786 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine biomarkers collected at admission and day three postarrest
Number of subjects: 195
Study 31205944 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified suction-assisted cartilage shaver for AO
Number of subjects: 39
Study 31206074 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year camp-based immersion family treatment for obesity
Number of subjects: 90
Study 31206074 — intervention group
Group type: COMPARATOR
Intervention: outpatient family-based treatment for obesity
Number of subjects: 90
Study 31206096 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) questionnaires
Number of subjects: 0
Study 31206096 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31206240 — intervention group
Group type: COMPARATOR
Intervention: Riociguat
Number of subjects: 0
Study 31206240 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil
Number of subjects: 0
Study 31206240 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil
Number of subjects: 0
Study 31206368 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of olaparib plus paclitaxel
Number of subjects: 0
Study 31206368 — intervention group
Group type: EXPERIMENTAL
Intervention: ATM-negative tumors
Number of subjects: 0
Study 31206368 — intervention group
Group type: EXPERIMENTAL
Intervention: ATM (Y170) assay
Number of subjects: 0
Study 31206368 — intervention group
Group type: EXPERIMENTAL
Intervention: ATM-deficiency defined by <25% tumor cell nuclei expressing ATM
Number of subjects: 0
Study 31206368 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of ATM levels by IHC
Number of subjects: 0
Study 31207172 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 59
Study 31207442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve-guided percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 31207442 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 0
Study 31207465 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-florbetaben (FBB)
Number of subjects: 25
Study 31207561 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled pharmacotherapy for psychotic depression
Number of subjects: 0
Study 31208123 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitary shoes
Number of subjects: 26
Study 31208123 — intervention group
Group type: COMPARATOR
Intervention: Barefoot condition
Number of subjects: 26
Study 31208356 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation
Number of subjects: 10
Study 31208356 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 10
Study 31208466 — intervention group
Group type: EXPERIMENTAL
Intervention: DF-PAL (Dairy Farmers with PAL)
Number of subjects: 186
Study 31208466 — intervention group
Group type: EXPERIMENTAL
Intervention: NF-PAL (Non-farmers with PAL)
Number of subjects: 186
Study 31208466 — intervention group
Group type: EXPERIMENTAL
Intervention: DF-PAL
Number of subjects: 186
Study 31208466 — intervention group
Group type: COMPARATOR
Intervention: NF-PAL
Number of subjects: 186
Study 31208471 — intervention group
Group type: EXPERIMENTAL
Intervention: VIVIFRAIL multicomponent exercise programme
Number of subjects: 240
Study 31208471 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 240
Study 31208944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus FCR (Fludarabine, Cyclophosphamide, Rituximab); Ibrutinib 420 mg/day for 7 days, followed by up to six 28-day cycles of FCR.
Number of subjects: 85
Study 31208944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus FCR
Number of subjects: 85
Study 31208955 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomics-informed computational biology modeling (CBM)
Number of subjects: 50
Study 31208955 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory validation of CBM predictions
Number of subjects: 50
Study 31209482 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD/CRT-D replacement/upgrade
Number of subjects: 983
Study 31210922 — intervention group
Group type: EXPERIMENTAL
Intervention: VEMOFIT (value-based emotion-focused educational program)
Number of subjects: 0
Study 31210922 — intervention group
Group type: COMPARATOR
Intervention: Attention-control program
Number of subjects: 0
Study 31210950 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transfer (FMT)
Number of subjects: 240
Study 31211145 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified method of contrast echocardiography
Number of subjects: 506
Study 31211145 — intervention group
Group type: COMPARATOR
Intervention: Traditional method of contrast echocardiography
Number of subjects: 506
Study 31211158 — intervention group
Group type: EXPERIMENTAL
Intervention: Live respiratory syncytial virus (RSV) candidate vaccine LIDcpΔM2-2, single intranasal dose of 10
Number of subjects: 11
Study 31211158 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 11
Study 31211764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile PDA with hemodynamically significant features
Number of subjects: 50
Study 31211764 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive PDA
Number of subjects: 50
Study 31211764 — intervention group
Group type: EXPERIMENTAL
Intervention: No evidence of PDA
Number of subjects: 50
Study 31211792 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed bivalent (Vibrio cholerae O1 and O139) whole-cell oral cholera vaccine (SHANCHOL; Shantha Biotechnics) - 2 doses, 14 days apart
Number of subjects: 200
Study 31212080 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) administered post-transplant
Number of subjects: 63
Study 31212162 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime breastfeeding for at least 7 months
Number of subjects: 152
Study 31212162 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity
Number of subjects: 152
Study 31212162 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age at first live birth
Number of subjects: 152
Study 31212162 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche
Number of subjects: 152
Study 31212162 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of oral contraceptives
Number of subjects: 152
Study 31212293 — intervention group
Group type: COMPARATOR
Intervention: No IVH
Number of subjects: 1112
Study 31212293 — intervention group
Group type: EXPERIMENTAL
Intervention: IVH without obstructive hydrocephalus (IVH-w/o-EVD)
Number of subjects: 1112
Study 31212293 — intervention group
Group type: EXPERIMENTAL
Intervention: Graeb score >2
Number of subjects: 1112
Study 31212683 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational text messages (3 messages weekly for 12 weeks)
Number of subjects: 79
Study 31212833 — intervention group
Group type: EXPERIMENTAL
Intervention: P28GST administration
Number of subjects: 0
Study 31212833 — intervention group
Group type: EXPERIMENTAL
Intervention: P28GST treatment in Crohn's disease patients
Number of subjects: 0
Study 31212833 — intervention group
Group type: COMPARATOR
Intervention: Fecal microbiota transplantation from P28GST-immunized mice
Number of subjects: 0
Study 31212934 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity
Number of subjects: 6672
Study 31212934 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MedDiet)
Number of subjects: 6672
Study 31212934 — intervention group
Group type: COMPARATOR
Intervention: Physical Activity and Mediterranean Diet (joint effect)
Number of subjects: 6672
Study 31212934 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean Body Mass
Number of subjects: 6672
Study 31212997 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy
Number of subjects: 36
Study 31213500 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib (30 mg b.i.d.) and Pexidartinib (400 mg every morning and 200 mg every evening)
Number of subjects: 2
Study 31213778 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based intervention for improving medication adherence
Number of subjects: 0
Study 31213778 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 31213865 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast for 6 weeks
Number of subjects: 8
Study 31213865 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 8
Study 31214997 — intervention group
Group type: EXPERIMENTAL
Intervention: Trelagliptin 100 mg once weekly for 12 weeks
Number of subjects: 218
Study 31214997 — intervention group
Group type: COMPARATOR
Intervention: Daily DPP-4 inhibitor for 12 weeks
Number of subjects: 218
Study 31214997 — intervention group
Group type: EXPERIMENTAL
Intervention: Trelagliptin 100 mg once weekly
Number of subjects: 218
Study 31214997 — intervention group
Group type: COMPARATOR
Intervention: Daily DPP-4 inhibitor
Number of subjects: 218
Study 31214997 — intervention group
Group type: EXPERIMENTAL
Intervention: Trelagliptin and daily DPP-4 inhibitors
Number of subjects: 218
Study 31215195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent imaging agent IS-001
Number of subjects: 0
Study 31215234 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation intervention (2-week protocol, adapted from Jon Kabat-Zinn's Mindfulness-Based Stress Reduction course)
Number of subjects: 10
Study 31215264 — intervention group
Group type: EXPERIMENTAL
Intervention: Betrixaban
Number of subjects: 0
Study 31215264 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin and fondaparinux (Control)
Number of subjects: 0
Study 31215448 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC sevoflurane in 40% oxygen
Number of subjects: 29
Study 31215603 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization program including progressive passive mobilization, positioning, discussion of mobilization goals, cycle ergometer, and virtual reality games.
Number of subjects: 6
Study 31215603 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization protocols implemented by a multidisciplinary team.
Number of subjects: 6
Study 31215715 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line glucose-lowering therapy
Number of subjects: 15992
Study 31215813 — intervention group
Group type: EXPERIMENTAL
Intervention: Disrupted sleep
Number of subjects: 0
Study 31215818 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31216011 — intervention group
Group type: EXPERIMENTAL
Intervention: Incretin-based therapies
Number of subjects: 0
Study 31216011 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous incretin infusions
Number of subjects: 0
Study 31216123 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart involvement
Number of subjects: 197
Study 31216123 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive proteinase 3 (PR3)-ANCA
Number of subjects: 197
Study 31216123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary hemorrhage
Number of subjects: 197
Study 31216123 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary red blood cell casts
Number of subjects: 197
Study 31216198 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine-18-Labeled Fluciclovine PET/CT
Number of subjects: 0
Study 31216218 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccination (exposed cohort)
Number of subjects: 1203